Group 1 - The core viewpoint of the article highlights the strong performance of China National Pharmaceutical Group (Sinopharm) in the pharmaceutical distribution industry, with a 17% year-on-year growth in net profit attributable to shareholders in Q3 2025 [1][5] - Sinopharm operates in three main segments: pharmaceutical distribution, medical device distribution, and retail, with a revenue of 584.5 billion RMB in 2024, maintaining a leading position in the Chinese pharmaceutical retail market [1][3] - The company has a robust distribution network covering over 700,000 terminal networks across various provinces, contributing to its market share growth [1][3] Group 2 - Sinopharm's actual controller is China National Pharmaceutical Group, with a clear distribution of business across its subsidiaries, including significant stakes in listed companies [2] - The company has experienced a compound annual growth rate (CAGR) of approximately 9% in revenue over the past seven years, with a slight decline in revenue in 2024 [3][5] - The net profit for 2024 was approximately 7.05 billion RMB, reflecting a 22.14% year-on-year decrease due to impairment provisions [5][6] Group 3 - The pharmaceutical distribution segment has shown a CAGR of about 7% from 2018 to 2024, with a focus on high-value clinical products and marketing service expansion [9][10] - The medical device distribution segment has also seen growth, particularly in the SPD (Smart Procurement and Distribution) business, which has expanded its coverage significantly [11][13] - The industry is experiencing increased concentration, benefiting leading companies like Sinopharm, which holds over 20% market share [14]

来源：基本面力场 最近有一家公司正在申请IPO，公司全称是安徽林平循环发展股份有限公司，股票简称林平发展，保荐 机构是国联民生证券。 林平发展的核心业务是纸制品的制造和销售，主要产品为瓦楞纸和箱板纸，瓦楞纸的销售占比约在30% 左右，箱板纸的销售占比超70%，且近年来箱板纸产品的销售占比呈现小幅提升的趋势。 客观来说，当前造纸行业整体经营形势并不是很乐观，产能过剩、需求不足等问题长期存在，且部分企 业为了争夺市场份额，不惜采取低价竞争策略，甚至在低于成本价的情况下销售，导致行业"内卷"严 重。有数据统计，2024年造纸全行业营业收入高达1.46万亿元，但利润总额仅为520亿元，利润率低至 3%。 在此背景下，林平发展的IPO能够走到审核阶段，想必是"有两把刷子"的。从这家公司的业绩数据来 看，力场君就很能感受到其经营韧性，正是一家行业内"优等生"该有的品质。 这种韧性首先体现在即便遭遇不利因素，营业利润仍稳得住。这一点突出体现在2024年，在行业内卷严 重、业内头部公司出现较大亏损的宏观背景下，加之受台风"贝碧嘉"影响致萧县厂区被洪水浸泡、生产 经营收到较大影响的微观不利因素，林平发展仍能收获1.79亿元营业 ...

Core Viewpoint - Cinda Securities reports that China National Pharmaceutical Group (National Pharmaceutical Holdings) is nearing the end of its inefficient business adjustments, with profit improvements expected by Q3 2025. The company is benefiting from increased industry concentration and the development of innovative businesses, leading to a gradual increase in dividend payout ratios and a current valuation below historical averages. The initial coverage gives the company a "Buy" investment rating [1]. Group 1: Profit Improvement and Business Adjustments - The adjustment of inefficient businesses is close to completion, with significant profit improvements observed. In Q3 2025, the sales expense ratio and management expense ratio decreased, resulting in a net profit margin increase of 0.2 percentage points, with a year-on-year growth rate of 17% in net profit attributable to shareholders [2]. - The year 2025 marks the end of the 14th Five-Year Plan and the base year for the 15th Five-Year Plan, focusing on quality improvement and business structure optimization. The company is expected to perform well in 2026, with profits likely to exceed expectations [2]. - The company has steadily increased its dividend payout ratio over the past four years, from 28.1% in 2021 to 30.98% in 2024, with an average annual increase of 0.96 percentage points. The average dividend yield over the past five years is 4.45%, and the current price-to-book (PB) ratio is approximately 0.71, below the five-year average of 0.81 [2][4]. Group 2: Industry Concentration and Growth Drivers - The concentration of the distribution industry has increased, with the market share of the top four companies rising from 38.38% in 2019 to 42.69% in 2023, with National Pharmaceutical Holdings holding a 20.36% market share in 2023. The compound annual growth rate (CAGR) of the company's pharmaceutical distribution revenue is approximately 7% from 2018 to 2024, with projected revenue of about 424.6 billion yuan in 2024 [3]. - Growth drivers for pharmaceutical distribution include increased industry concentration, optimization of product structure towards high-demand and high-value products, and the promotion of innovative service development. The CAGR for medical device distribution revenue is approximately 15.69%, with projected revenue of about 117.5 billion yuan in 2024 [3]. - In the retail sector, the company is advancing its "integrated wholesale and retail" strategy, with a CAGR of approximately 16% in retail revenue from 2018 to 2024. The revenue growth for the National Pharmacy is projected at 12.52%, while specialized pharmacies are expected to grow at a CAGR of about 23.64% [3]. Group 3: Future Planning and Governance Changes - The governance structure of the National Pharmaceutical Group underwent changes in 2024, with new leadership appointed. The company aims to achieve a strategic goal of becoming a top 100 company with a trillion yuan in revenue by the end of the 14th Five-Year Plan, and the planning for the 15th Five-Year Plan is set to begin in 2025 [4]. - The company’s dividend payout ratio has shown a steady increase, with a slight decline in the dividend yield to 3.47% in 2024 due to a decrease in profits. The current PB ratio is approximately 0.71, which is below the five-year average of 0.81 [4]. Group 4: Revenue and Profit Forecast - The company is projected to achieve revenues of 577.19 billion yuan, 597.83 billion yuan, and 619.32 billion yuan for the years 2025 to 2027, with year-on-year growth rates of -1%, 4%, and 4%, respectively. The net profit attributable to shareholders is expected to be 8.08 billion yuan, 8.75 billion yuan, and 9.52 billion yuan, with growth rates of 15%, 8%, and 9% [5].

Core Viewpoint - The regulatory environment for the securities industry is shifting towards a more positive stance, indicating significant growth potential during the "14th Five-Year Plan" period, which may act as a catalyst for market performance in the sector [1][11]. Group 1: Regulatory Changes and Benefits - Regulatory easing is expected to directly benefit core operations of securities firms by opening up capital space and leverage limits, enhancing capital utilization efficiency [4][14]. - The three main business areas likely to benefit from this regulatory shift include margin financing and securities lending, proprietary trading, and international business, with expectations of increased capital and leverage [4][14]. - The current industry leverage ratio stands at 4.42 times, indicating room for growth in capital utilization [4][14]. Group 2: Shift from Price to Value Competition - The regulatory body emphasizes a transition from price competition to value competition, encouraging firms to leverage their resources effectively and develop into internationally influential institutions [5][15]. - Smaller firms are advised to focus on niche markets and specialized services to create high-quality offerings, while larger firms should enhance their resource integration capabilities [5][15]. - This shift aims to move the industry from a "red ocean" of price competition to a "blue ocean" of comprehensive service offerings [5][15]. Group 3: Classification Regulation and Mergers - The regulatory framework will implement differentiated supervision, favoring high-quality institutions with relaxed regulations while enforcing stricter measures on underperforming firms [6][16]. - The promotion of mergers and acquisitions is expected to enhance industry competitiveness and resource allocation, aiming to create several leading firms with significant international influence during the "14th Five-Year Plan" [6][16]. - This consolidation is anticipated to increase industry concentration and achieve economies of scale [6][16]. Group 4: Investment Opportunities - As of December 5, 2025, the CSI All Share Securities Index shows a price-to-book ratio of approximately 1.47, indicating attractive valuation levels [9][19]. - The regulatory guidance is expected to facilitate a transition towards high-quality development, serving as a catalyst for valuation recovery in the sector [9][19]. - The focus on enhancing leverage and capital efficiency is projected to elevate the return on equity (ROE) for the industry, fostering a healthier and more efficient market ecosystem [9][19]. - Investors may consider the securities ETF (159842), which tracks the CSI All Share Securities Index, providing exposure to 49 leading firms in the sector with a low management fee of 0.15% [19].

Core Viewpoint - The retail chain pharmacy industry is experiencing intensified competition due to weakened demand, leading to a gradual supply-side contraction. The operational turning point for leading pharmacies is emerging, with a focus on the growth potential in 2026 through both organic and external expansion [1]. Group 1: Investment Recommendations - The recommendation is to maintain an "overweight" rating, focusing on leading chain pharmacies that are expected to benefit from supply-side clearing and demand-side recovery. The retail scale of China's physical pharmacies (including drugs and non-drugs) is projected to reach 611.9 billion yuan in 2024, a year-on-year decline of 1.8% [2]. - In the first three quarters of 2025, the industry scale is expected to reach 449 billion yuan, a year-on-year decline of 1.9%, but showing signs of recovery with a September scale of 53.8 billion yuan, a year-on-year increase of 0.8% and a quarter-on-quarter increase of 6.7% [2]. Group 2: Demand Side Analysis - The demand side is showing weakened consumption, with significant declines in sales of consumer-oriented products like health supplements. However, essential consumer products such as traditional and Western medicines are experiencing a quarter-on-quarter recovery, with a retail scale of 43.7 billion yuan in September 2025, reflecting a quarter-on-quarter growth of 6.9% and a year-on-year growth of 2.2% [3]. - The sales proportion of drugs in pharmacies has increased by 0.8 percentage points year-on-year to 81.4%, while the proportion of health supplements has decreased by 0.5 percentage points to 3.8% [3]. Group 3: Supply Side Dynamics - The supply-side clearing is leading to an increase in the concentration of leading chain pharmacies. The number of physical pharmacies reached a new high in 2024, exceeding 700,000, a growth of over 60% since the end of 2014. The average customer service level per store has dropped to about 2,000 people per store [4]. - The number of stores in the industry decreased by 4,000 in Q4 2024 and by 3,000 in Q1 2025, with leading chain pharmacies showing lower closure rates compared to smaller chains, indicating a potential increase in industry concentration [4]. Group 4: Future Outlook for Leading Pharmacies - Leading chain pharmacies are expected to recover first, with growth driven by both organic and external factors. The recent rise in flu cases is anticipated to boost sales of respiratory-related medications, with flu positivity rates reaching 8.6% in the 47th week, significantly higher than the same period in 2022-2024 [5]. - The current number of direct stores for leading chains is about 10,000, representing only 1.5% of the industry, indicating that the industry is still in the early stages of structural change, with long-term prospects for increased concentration [5].

Summary of Conference Call on Pharmacy Sector Industry Overview - The pharmacy sector is showing signs of recovery, with positive signals from industry policies and adjustments made by pharmacies, particularly leading pharmacies like YaoXingTang, which have achieved same-store sales growth through adjustments [1][2] - The three main trends in the pharmacy industry are prescription outflow, increased industry concentration, and diversified operations [1][3] Key Points Recovery Indicators - The pharmacy sector has been consolidating at the bottom for about a year since 2024, with leading pharmacies currently at historical valuation lows [2] - Positive changes in industry policies and pharmacy operations are evident, indicating a clear upward trend [2] Major Trends 1. **Prescription Outflow**: This long-term trend significantly contributes to increased customer traffic and sales, although online prescription transfer remains slow [3] 2. **Industry Concentration**: The concentration of the top ten pharmacies in China is around 30%, compared to 80% in Japan and 70% in the US, indicating substantial room for growth [3] 3. **Diversified Operations**: Successful implementation of comprehensive adjustments by leading pharmacies in 2026 is expected to significantly boost profits [4] Company Performances - **Yifeng Pharmacy**: Designated as a "gold stock" for December, with a valuation offering good value. Same-store sales are expected to recover to over 1% growth starting Q3 2025, with projected revenue growth returning to double digits in 2026, corresponding to a PE ratio of less than 14 [5] - **Dafeng Pharmaceutical**: Achieved a profit growth of 26% in the first three quarters of 2025, with a net profit margin increasing from 3% to nearly 6%. The company plans to restart its acquisition strategy, which is expected to support future performance [6] - **Laobaixing Pharmacy**: Same-store sales turned positive starting Q3 2025, with significant contributions from acquisitions. The company is also making progress in store adjustments [7] Future Expectations - **Yifeng Pharmacy**: Expected to see improved performance in 2026, with revenue growth projected to exceed double digits and a PE ratio of less than 14, indicating a favorable investment position [5] - **Dafeng Pharmaceutical**: Anticipated to achieve over 30% net profit growth for the year, with a strong performance trend continuing into the future [6] - **Yifeng Pharmacy's Adjustments**: Plans to increase the non-pharmaceutical product ratio to 40% over the next three to five years, with significant profit contributions expected from store adjustments [7] Industry Adjustments and Projections - The pharmacy sector is expected to conduct pilot adjustments in 150 stores in 2025, with plans for comprehensive adjustments in 2026. Adjusted stores are projected to achieve a sales share of over 30%, with daily sales increasing by 1,200 yuan and gross margins improving by 18% [7] - If 70% of stores implement these adjustments, the net profit increase could exceed 500 million yuan [7] Investment Opportunities - The pharmacy sector has largely moved past policy disruptions, with ongoing improvements in same-store sales and increasing industry concentration. Leading pharmacies are now at attractive valuation levels, with growth certainty in performance [9] - Recommendations include focusing on opportunities within the pharmacy sector, particularly on stable-performing leading pharmacies like Yifeng and Dafeng [9] Data Evaluation - Data Evaluation is actively expanding and collaborating with Taiwan's Dashi Pharmacy for pilot projects in Shandong, showing optimism for future performance despite limited current data [10]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

Investment Rating - The report suggests a focus on three main investment lines, particularly highlighting the potential for significant growth in the securities and insurance sectors [2][4]. Core Insights - The report indicates that the recent merger activities among major securities firms, such as the planned absorption of Dongxing Securities and Xinda Securities by CICC, are expected to enhance industry concentration and catalyze valuation recovery in the brokerage sector [1][43]. - It emphasizes the strong performance of listed brokers in Q3, with a current price-to-book ratio (PB) of 1.34x, recommending brokers with solid fundamentals but mismatched valuations [2]. - The report also highlights the promising growth prospects in the multi-financial sector, particularly for the Hong Kong Stock Exchange, which is expected to benefit from deepening connectivity and increased activity from A-share companies listing in Hong Kong [2]. Summary by Sections Securities Sector - The report notes a significant merger in the securities industry, with CICC planning to merge with Dongxing Securities and Xinda Securities, which is the third major merger in 2024, following the mergers of Guotai Junan and Haitong Securities, and Guoxin Securities acquiring Wanhe Securities [1]. - It highlights the expected impact of this merger on industry concentration and valuation recovery for the brokerage sector [1]. Insurance Sector - The report discusses the recent guidelines issued by the China Actuarial Society regarding the expense allocation for life insurance products, which aims to enhance the scientific and reasonable pricing of insurance products [3]. - It anticipates a double-digit growth in new premium income in the short term, supported by a decrease in liability costs and improved industry concentration in the long term [4]. - The report recommends focusing on leading insurance companies with strong business quality and low liability costs, as well as those undergoing transformation towards dividend insurance [4]. Market Review - The report provides a market review indicating that the CSI 300 index fell by 3.8%, with the non-bank financial sector declining by 4.4%, underperforming the index [10]. - It notes the performance of various sub-sectors, with securities and insurance stocks experiencing declines of 4.9% and 3.0%, respectively [10]. Data Tracking - The report includes data on brokerage activities, noting a decrease in average daily A-share trading volume to 18,650 billion yuan, a decline of 8.7% [15]. - It also highlights significant growth in the issuance of equity public funds and bond underwriting, with IPO and refinancing raising 902 billion and 8,623 billion yuan, respectively, in October 2025 [15].

（文章来源：证券日报） 证券日报网讯恩捷股份11月21日发布公告，在公司回答调研者提问时表示，中小企业缺乏扩产信心和能 力，未来少数供给端的增量主要来源于头部企业，预计行业集中度将进一步提升。 ...

Group 1: Market Trends and Demand - There is a trend of switching from dry-process to wet-process separators in energy storage batteries, with some customers already making this transition [2] - The demand for energy storage batteries remains strong, and the demand for power batteries continues to grow, leading to an overall increase in downstream demand [3] Group 2: Supply and Production Capacity - The new production capacity in the separator industry this year is lower than last year, resulting in reduced effective capacity formation, indicating an improvement in supply [2] - The expansion cycle in the separator industry is long and capital-intensive, making it difficult to increase production amid low profit levels and long recovery periods [3] Group 3: Industry Competition and Pricing - The future competition landscape in the separator industry is expected to see increased concentration, with supply growth primarily coming from leading enterprises due to the lack of confidence and capability among small and medium-sized enterprises [4] - The pricing of separator products is influenced by supply and demand as well as product performance, with expectations for gradual recovery in prices and profit levels as downstream demand continues to rise [5] Group 4: Current Orders and Production Utilization - The company currently has a robust order book and high production utilization, with stable growth in downstream customer demand and orders [6] - The company anticipates further growth in shipment volume in 2025, supported by strong demand in the energy storage sector [6]